PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Hepatology. Author manuscript; available in PMC 2010 July 1.
Published in final edited form as:
PMCID: PMC2727352
NIHMSID: NIHMS116778

Mutations in the Hepatitis C Virus Polymerase That Increase RNA Binding Can Confer Resistance to Cyclosporine A

Abstract

Hepatitis C virus (HCV) infection leads to acute and chronic liver diseases, and new classes of anti-HCV therapeutics are needed. Cyclosporine A (CsA) inhibits HCV replication, and CsA derivatives that lack the immunosuppressive function are currently in clinical trials as candidate anti-HCV drugs. Here, we characterize several independently derived HCV replicons with varying levels of CsA resistance due to mutations in nonstructural protein 5B (NS5B), the HCV-encoded polymerase. Mutant HCV replicons engineered with these mutations showed resistance to CsA. The mutations reside in two distinct patches in the polymerase: the template channel and one face of a concave surface behind the template channel. Mutant NS5B made by cells expressing the HCV replicon had increased ability to bind to RNA in the presence of CsA. Purified recombinant NS5B proteins containing the mutations were better at de novo initiated RNA synthesis than the wild-type control. Furthermore, the mutant proteins were able to bind RNA with approximately eightfold higher affinity. Last, mutation near the template channel alleviated the lethal phenotype of a mutation in the concave patch, P540A. This intramolecular compensation for the HCV replicase function by amino-acid changes in different domains was further confirmed in an infectious cell culture-derived virus system.

Conclusion

Increased level of CsA resistance is associated with distinct mutations in the NS5B gene that increase RNA binding in the presence of CsA, and the intramolecular communications between residues of the thumb and the C-terminal domains are important for HCV replicase function.

Keywords: HCV infection, RNA-dependent RNA polymerase, Drug resistance, RNA synthesis, Viral mutations

Cyclosporine A (CsA), a commonly used immunosuppressant for transplant patients, has recently emerged as a potential new anti-HCV therapeutic. CsA and its derivatives potently inhibit HCV replication both in cell-culture systems and in mice with transplanted human liver (1-3), although no consensus has emerged on the in vivo benefits of using CsA over Tacrolimus (FK506), a compound that lacks anti-HCV effect in vitro, for HCV-infected liver-transplant patients (4-9). More recent clinical trials with a CsA derivative, DEBIO-025, yield promising results in HIV and HCV coinfected patients, but drug resistance in vivo has not been studied (10).

Studies of the antiviral effect of CsA on HCV replicons has led to the identification of Cyclophilin (CyP) as an essential cofactor for HCV replication (11-13); point mutations in nonstructural protein 5B (NS5B) and NS5A that are associated with CsA resistance in vitro (14, 15). In addition, NS5B interacts with both CyPA and CyPB both in vitro and in vivo (12, 13). These data establish NS5B as an indirect viral target for the CsA-mediated inhibition of HCV replication. The CyPA-NS5B interaction has also been shown to be the principal mediator of cyclosporine resistance in vitro (12).

How CyPA affects NS5B function is unclear. The crystal structure of HCV NS5B lacking the C-terminal transmembrane domain has been solved. It adopts a typical right-handed shape that contains finger, palm, and thumb domains surrounding the active site (16-18). Characterization of allosteric, nonnucleoside inhibitors revealed extensive communication between the different domains (19). Here we identify a series of mutations in NS5B that conferred resistance to CsA and show that the mutations can affect RNA binding and synthesis by the HCV polymerase.

Experimental Procedures

Compounds and cell lines

Cyclosporine A was purchased from Alexis Corporation (San Diego, CA). GS5- and CsA-resistant replicons have been described previously (14, 20). All replicon cells are routinely cultured in DMEM with 10% FBS and 500 μg/ml of G418.

Replicon Sequencing, site-directed mutagenesis and Replication assays

These experiments were performed using published procedures (14, 20). Detailed information on these methods can be found in the supplemental methods. Primer sequences used in the cloning and sequencing are shown in the supplemental tables 1 and 2.

Molecular Biology Assays

Transient replication was measured by isolation of total cellular RNAs from cells 7 h, 4 days, and 10 days after electroporation of the Rep1b or JFH-1 RNA. We performed real-time RT-PCR with a SYBR® Green PCR kit (Applied Biosystems) to detect HCV IRES and GAPDH expression. Sequences of the qRT-PCR primers are shown in the supplemental table 3. In vitro transcription, electroporation, colony formation, and Poly-U RNA binding assays were performed as previously described (12, 14).

Infections and fluorescence staining

Infection of Huh-7.5 cells by cell culture-derived virus was performed as previously described (21). Immunostaining of infected Huh-7.5 cells was carried out according to standard methods with a mouse monoclonal antibody against the core protein (Affinity Bioreagents, Golden, CO) and a FITC-conjugated goat-anti-mouse secondary antibody for detection (Sigma, St. Louis, MO).

Protein purification and RdRp assays

Wild-type and mutant versions of the NS5B Δ21 were expressed in E. coli as C-terminal 6xHis tagged proteins and purified first by a metal ion chromatography and then with polyuridylate resins. Standard RdRp assays were performed as previously described (22). Protein concentrations were determined by comparison with known concentrations of BSA in Coomassie blue-stained SDS-PAGE.

Differential scanning fluorimetry

Differential scanning fluorimetry was performed in a Stratagene MX3005P machine with an excitation of 492 nm and emission of 610 nm. Each sample was prepared in a total volume of 50 μl containing solutions of protein at 2.5 μM final concentration, SYPRO orange (Molecular probes) at 2.5 × final concentration. The samples were heated at a rate of 0.5°C/min, from 25 to 95°C, and the Tm values were calculated from the maximum of the first derivative with KaleidaGraph software (Synergy Software, Reading, PA).

Fluorescence anisotropy assay

Measurements were made with an LS55 spectrometer (Perkin-Elmer) and cuvettes with an optical path length of 0.4 cm at 22°C. The fluorescein-labeled RNA SL-UC was at 0.2 μM in 50 mM Tris-Cl (pH 7.5) and 25 mM NaCl. The final volume of protein added did not exceed 5% of the initial sample volume. Excitation wavelength was 495 nm, and each emission was scanned from 510 to 560 nm. The average of 10 scans was taken per data point and the data was analyzed by nonlinear least-square fitting using KaleidaGraph.

Results

Isolation of replicon RNA with distinct levels of CsA resistance

We have recently isolated CsA-resistant replicons using a combination of antibiotic selection and cell sorting (14). When single-cell clones of the resistant population were analyzed, various levels of CsA resistance were observed (Fig. 1A). The three single-cell clones with the highest levels of resistance were RS1-2, RS1-8, and RS1-9 (Fig. 1A); other clones had lower levels of resistance, similar to that of RS1-10 (supplemental Fig. 1A). To confirm that the CsA resistance of these single-cell clones was indeed conferred by the replicon RNA, we introduced total RNAs isolated from these cells, which contain the replicon RNAs, into naïve Huh-7.5 cells. The new replicons are designated RS1-2.2, RS1-8.2, RS1-9.2, and RS1-10.2, respectively. The replicon RNAs from all these clones phenocopied the resistant phenotype to the new replicon cells (supplemental Fig. 1B). Importantly, the relative level of resistance was maintained in the progeny replicons, demonstrating that the replicon RNAs in these clones contain distinct mutations that are responsible for the resistant phenotype.

Fig. 1Fig. 1
NS5B mutations that confer CsA-resistance. (A) Single-cell clones exhibit distinct levels of CsA resistance. The replicon cells were treated with increasing concentrations of CsA for 4 days before being analyzed by western blotting to detect NS5A expression. ...

Identification of Point mutations in NS5B that confer resistance

HCV NS5B gene, which encodes the viral RdRp, has been implicated in the CsA-mediated inhibition of HCV and CsA resistance in vitro (12-15). We sequenced the NS5B region of the single cell clones and compared them to the wild-type sequence represented by GS5 replicon. Despite having a similar level of resistance, RS1-8, RS1-9 and RS1-2 contained different mutations in the NS5B coding region. A single common I432V mutation was found in RS1-2 NS5B while combinations of two mutations I11V/I454V and Q438R/E440G were found in RS1-8 and RS1-9, respectively. To determine whether these mutations could confer CsA resistance, we engineered them into a wild-type genotype 1b replicon, Rep1b, and assayed the resultant constructs for CsA resistance. Expression of the NS5A protein of Rep1b was below the detectable level when the replicon was treated with 0.375 μg/ml of CsA. In contrast, NS5A could be detected when the mutant replicons were treated with the same concentration of CsA (Fig. 1B). This result was confirmed with a colony-formation assay. In the absence of CsA treatment, electroporated replicon RNAs resulted in formation of G418-resistant colonies as a result of the expression of the neomycin phosphotransferase gene carried by these replicons. Inclusion of 0.375 μg/ml of CsA abolished the ability of the wild-type replicon (Rep1b) to form colonies, whereas the three mutant replicon RNAs retained colony formation (Fig. 1C). No significant differences were observed between the mutant and wildtype replicons’ ability to form colonies in the absence of CsA. These results demonstrate that these NS5B mutations are sufficient to confer increased CsA resistance without enhancing replication. However, the full level of CsA resistance of the original resistant isolates may require mutations in other genes (compare the CsA dosages in Fig. 1A and Fig. 1B and see supplemental table 4).

The CsA-resistance mutations locate to two functionally-related regions in NS5B structure

All of the mutations lie within two regions of the NS5B structure (Fig. 2A). First, mutations I432V, I11V and V405L are within the template channel or the Δ1 loop that extends from the finger subdomain to the thumb subdomain to form a latch over the template channel. This locking mechanism is primarily due to hydrophobic interactions between the Δ1 loop and the residues on the outer surface of the template channel (22). The second group of mutations, Q438R, E440G, I454V, and W550R, lie along one side of a concave surface at the back of the template channel, along a groove. Mutation R556V could not be mapped because it was not present in the crystal structure, but the trajectory of the C-terminal tail is projected to be near the template channel. To extend this analysis, we also examined the locations of the two mutations in NS5B identified by Fernandes et al. (15), S556G and P538T. S556G is located within the template channel and P538T is within the same side of the concave surface of NS5B, lining the aforementioned groove. A compilation of all nine mutations in the NS5B structure is shown in Fig. 2B; including a cut-away view that better exposes the locations of the mutations within the template channel.

Fig. 2Fig. 2
Locations of the mutations in NS5B that conferred resistance to CsA. (A) Models of the mutations in NS5B from RS1-2, RS1-8, RS1-9, and RS1-10. The structure of the NS5B protein is from Ago et al. (16) (pdb: 1QUV). Several features in the structures serve ...

RNA binding by HCV replication proteins in the presence of CsA

On the basis of their locations in the NS5B structure, we hypothesize that the mutations could affect RNA binding by NS5B. To test this hypothesis, we assayed whether NS5B produced in cells could bind poly-U (pU) RNA in vitro in a CsA-sensitive manner (13). Cell lysates were incubated with pU resin, then washed and subjected to western blot analysis with antiserum to NS5B. Binding to protein G Sepharose served as a negative control. All NS5B variants were able to bind pU RNA in the absence of CsA (Fig. 3A). The interaction between the wild-type NS5B and pU RNA was reduced by more than 90% upon CsA treatment. In contrast, all three of the NS5B proteins produced by mutant replicons retained pU RNA binding when treated with CsA (Fig. 3A). The reductions in RNA binding by mutant proteins containing I432V, Q438R/E440G, and I11V/I454V were 0%, 5-10%, and 40-50%, respectively (Fig 3B). Note that these cells were treated with CsA for only 22 hrs, a time at which total NS5B protein level has not yet decreased. Longer treatment with CsA (>24 hours) would have resulted in a reduction in total NS5B.

Fig. 3
CsA-resistant RNA binding of the mutant NS5B proteins. (A) An in vitro poly-U RNA binding by NS5B. Cell lysates of CsA-treated (8 μg/ml) or untreated Rep1b or mutant replicon cells were incubated with either poly-U RNA-conjugated Sepharose or ...

To further determine if the mutations in NS5B that confer resistance to CsA affect NS5B activity, we expressed several of the mutants in E. coli in a form that lacked the C-terminal transmembrane domain (NS5BΔ21). The mutant proteins include I432V, I11V/I454V, Q438R/E440G, and a mutant that contained all five mutations (I11V, I432V, I454V, Q438R, and E440G), named Mut5 (Fig. 4A).

Fig. 4
Activity of recombinant NS5B proteins containing CsA-resistant mutations. (A) Coomassie blue-stained SDS-PAGE of the recombinant proteins purified for the experiments presented here and in Fig. 6. The purified proteins have been adjusted to be of comparable ...

The HCV RdRp can initiate RNA synthesis de novo from the 3′ end of the viral genome (23, 24) or by extension from a primed template (25). Both activities could be measured in the same reaction with RNA LE19 that exists in equilibrium between a monomer and a dimer. The monomer forms an intramolecular hairpin that directs de novo initiation to produce a 19-nucleotide (nt) product. A dimer can serve as the template-primer complex for an extension reaction 32 nt in length (22) (Fig. 4B). In addition, template-switch products that are multimers of the 19-nt RNA are also produced from some of the de novo initiated 19-mers will (26). All mutant proteins retained the ability to synthesize the de novo transcript, the primer-extended products and the template switch products (Fig. 4C), indicating that the mutations that conferred resistance to CsA did not affect residues of the polymerase that are essential for catalytic activity.

The mutant proteins had more subtle differences with regard to RNA synthesis. First, RNA synthesis by I432V was increased several folds (Fig. 4C). Higher template concentrations were previously reported to inhibit RNA synthesis by Δ21 protein (21). In contrast, I432V was not inhibited in RNA synthesis at higher ligand concentrations (supplemental Fig. 2). Second, mutants Q438R/E440G, I11V/I454V, and Mut5 produced up to 4.6-fold more of the 19-nt de novo initiated RNA than of the 32-nt primer-extension product (Fig. 4D). Notably, I432V produced a ratio of the de novo-initiated and the primer-extended products similar to that of Δ21, suggesting that I432V is functionally distinct from the other mutants. Because Mut5 also contained the I432V mutation, the effects of the other mutations on the ratio of RNA synthesis appear to dominate that of I432V.

Spectroscopic analysis of select mutant RdRps

The conformation of the HCV RdRp is linked to the mode of RNA synthesis. To examine the effects of the mutations on NS5B conformation, we selected mutant proteins I432V (near the template channel) and Q438R/E440G (in the concave surface) as representing the two classes of mutant proteins. Differential scanning fluorimetry (27) was used to measure proteins’ unfolding as a function of temperature. The assay uses SYPRO orange, which fluoresces when it binds to hydrophobic regions of proteins that are exposed upon thermal denaturation. Both I432V and Q438R/E440G differed distinctly in thermal denaturation profiles from Δ21 (Fig. 5A) and from each other, in agreement with the observed differences in RNA synthesis (Fig. 4C). The functional and spectroscopic analyses support the model that the CsA-resistant mutations affect the conformation of the NS5B protein.

Fig. 5
Spectroscopic characterizations of Δ21 and mutant proteins I432V and Q438R/E440G. (A) Differential scanning fluorimetry used to compare protein unfolding rates. Temperature increase was regulated by a Stratagene Mx3005P real-time PCR machine. ...

RNA binding by recombinant HCV RdRps

A fluorescence anisotropy assay was used to determine the affinity of RdRp-RNA binding. The RNA used was chemically synthesized to contain 5′ fluorescein (Fig. 5B) and a stable hairpin needed for efficient de novo initiation of RNA synthesis (28, 29). The binding isotherms for the three proteins were complex to fit, perhaps reflecting that the proteins may exist in equilibrium of two or more conformers, but when fitted to the same hyperbola equation, the affinities for SL-UC binding were 16 μM for Δ21 and less than 2 μM for I432V and Q438R/E440G (Fig. 5B). The apparent Kd values were reproducible within 10% in two independent experiments. These results show that mutations that conferred CsA resistance can increase RNA binding by NS5B in the absence of other proteins. Strikingly, both I432V (near the template channel) and Q438R/E440G (the concave surface of the RdRp), conferred increased RNA binding by the HCV RdRp.

Rescue of P540A lethal phenotype by NS5B mutations

We sought additional evidence for the functional relationship between the template channel and the concave surface of the HCV RdRp. A point mutation, P540A, that resides in the concave surface of the HCV RdRp abolished the replication of a genotype 1b replicon (13) and I432V rescued replication when engineered into the P540A background (14), demonstrating communication between the mutations at the two patches. We tested all the CsA-resistance mutations for their ability to alleviate the lethal effect of P540A in a transient replication assay. Replicon RNAs carrying P540A or P540A plus the CsA-resistance mutations were delivered into Huh-7.5 cells by electroporation. Total RNAs were extracted and analyzed by real-time RT-PCR. The input RNAs were at comparable levels in all the replicon derivatives at 7 h. After 4 days in culture, however, the P540A RNA had decreased to that of the negative control whereas the replicon derivatives had levels close to that of the wild type (Fig. 6). At day 10, the RNA levels of P540A/Q438R and P540A/E440G were lower than that of the wild type but three orders higher than that of P540A (Fig. 6A). The colony-formation assay results confirmed these observations (Fig. 6B). These results provide additional evidence that the two patches in the NS5B protein affected by CsA are functionally related.

Fig. 6
CsA-resistance mutations alleviate a lethal mutation at the C-terminal domain of NS5B. (A) Transient replication of Rep1b, P540A, and the derivatives. One μg of in vitro transcribed replicon RNAs was electroporated into Huh-7.5 cells, and total ...

A naturally occurring I454V variation averts the lethal effect of P540A mutation

The NS5B gene of GT2a carries a valine at position 454 instead of an isoleucine in the wild-type sequence. Importantly, the JFH-1 isolate of the GT2a genome can efficiently producing infectious particles in cell culture (30). To examine if Val454 could counteract the lethal phenotype of P540A in this genetic background, we engineered the P540A mutation into the JFH-1 genome and examined its effect on viral replication and infection of this isolate. In the transient replication assay, the P540A mutant was impaired in its ability to replicate but accumulated to a level higher than a non-viable control virus (GDD changed to GND in the catalytic core of NS5B) (Fig. 7A). In contrast, the double mutant of V454I and P540A (PAVI) was not viable whereas the V454I single mutant replicated close to wild-type level (Fig. 7A). There is a significant decrease in RNA level from 7 hour to day 4 for all the samples, likely a result of the higher amount of input RNA (10 μg as opposed to 1 μg used for the replicons in Fig. 6A) needed to produce infectious viruses. Nevertheless, for the wild-type, V454I, and P540A, the RNA level stabilized from day 4 through day 10, indicating sustained replication. Furthermore, when the supernatants from these cells were tested for their abilities to infect naïve Huh-7.5 cells, similar results were obtained (Fig. 7B). These results strongly suggest that the presence of a naturally occurring Valine at position 454 could prevent the lethal effect of P540A in an experimental setting that recapitulates the full cycle of HCV infection.

Fig. 7
Intramolecular compensation for P540A by valine at position 454 in an infection system. (A) Ten μg of in vitro transcribed JFH-1 and its derivative RNAs were electroporated into Huh-7.5 cells. Transient replication assay was performed as described ...

Discussion

Here, we report that mutations in the HCV polymerase that confer CsA-resistant replication increased RNA binding by NS5B, which is an indirect viral target of CsA’s inhibitory effect on HCV replication. Together with our previous report that CyPA interacts with NS5B and regulates HCV replication (12), these results suggest a model in which CyPA assists NS5B in binding RNA for HCV RNA synthesis. When mutations arise within NS5B that improve RNA binding, CyPA is not as necessary for NS5B function. Structural analysis revealed that the mutations associated with CsA resistance and a lethal mutation for which they can compensate are located in two distinct patches in NS5B, one near the template channel and one on the back of the template channel. The two patches both affected the same activity, perhaps RNA binding with or without CyPA. Although the template channel certainly contacts the RNA, the patch behind the template channel may serve to stabilize RNA binding either directly or with assistance from CyPA.

NS5B exists in a closed conformation that is correlated with de novo initiation which, on the basis of the ternary structure of the phage ϕ6 RdRp, is likely to be the form that binds single-stranded RNA for de novo initiation (31). The template channel is too narrow, however, to accommodate the double-stranded RNA intermediate that must form during RNA synthesis; the RdRp must assume a more open conformation during elongative RNA synthesis (22). The open and closed conformations probably exist in equilibrium and we propose that CyP and/or mutations within the RdRp could affect the equilibrium. With the CsA mutations, the increased de novo initiation versus primer extension by several of the mutations led us to propose that at least some of the mutations affect the conformation of the RdRp, especially mutations I432V and I11A, which could contact the Δ1 loop.

The NS5B mutations did not completely restore CsA resistance when engineered into a Con1 replicon background. Mutations elsewhere in the genome, particularly in the NS5A region, can probably augment the CsA resistance in combination with the NS5B mutations (14, 15). NS5A has been proposed to serve as a cofactor for NS5B, and interactions between the two have been reported (32, 33). NS5A-NS5B interaction may therefore modulate the conformation of NS5B and NS5A mutations may synergize with the NS5B mutations to increase CyP or RNA-binding. Interestingly, although the CsA-resistant replicons contained mutations in NS5A and NS3 (supplemental table 4), these mutations were also found in GS5, which is a CsA-sensitive replicon (12, 14). It is possible that mutations in other NS proteins, although unable to confer resistance by themselves, can augment CsA-resistance when combined the NS5B mutations.

Polymorphism of the HCV NS genes may affect HCV replication fitness and drug sensitivity in vivo. Although the P540A is clearly lethal to genotype 1b replicon, an alanine at position 540 exists in many naturally occurring isolates. Interestingly, all these isolates also contain at least one of the rescuing mutations that we identified as natural variations (14). Taking advantage of the naturally occurring I454V variation in the JFH-1 isolate, we confirmed the intramolecular compensation using a full-length infection system. These results demonstrate that the mutations we found to confer CsA resistance in cultured cells could be found in natural HCV isolates. Also of note, the concentrations of CsA that we used here to select resistant replicons are in the same range of the blood concentrations of CsA and DEBIO-025 in liver transplant and HCV infected patients, respectively. These data suggest that CsA-based therapies may have varying effects based on the patient population.

Supplementary Material

Supp Data

Supp Fig 01

Supp Fig 02

Supp Legend

Supp Tables

ACKNOWLEDGMENTS

We thank Drs. Takaji Wakita and Charlie Rice for reagents, Ruth Didier for assistance with flow cytometry, and Dr, Anne B. Thistle for proofreading.

Funding sources: This work was supported by the James and Esther King Biomedical Research Program (HT) and by NIH/NIAID AI073335 (CK).

Abbreviations

HCV
hepatitis C virus
GT
genotype
NS5B
nonstructural protein 5B
wt
wild-type
RdRp
RNA dependent RNA polymerase

References

1. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology. 2003;38:1282–1288. [PubMed]
2. Nakagawa M, Sakamoto N, Enomoto N, Tanabe Y, Kanazawa N, Koyama T, Kurosaki M, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun. 2004;313:42–47. [PubMed]
3. Inoue K, Umehara T, Ruegg UT, Yasui F, Watanabe T, Yasuda H, Dumont JM, et al. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology. 2007;45:921–928. [PubMed]
4. Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshiba M. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol. 2003;38:567–572. [PubMed]
5. Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila-Pico C, Machicao VI, Cabrera R, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl. 2006;12:51–57. [PubMed]
6. Guitard J, Sandres-Saune K, Kamar N, Ribes D, Faguer S, Esposito L, Lavit M, et al. Hepatitis C virus viral load after conversion from tacrolimus to cyclosporine in liver transplant patients: a pilot study. Transplant Proc. 2007;39:2603–2605. [PubMed]
7. Hilgard P, Kahraman A, Lehmann N, Seltmann C, Beckebaum S, Ross RS, Baba HA, et al. Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation: effects on virus replication and recurrent hepatitis. World J Gastroenterol. 2006;12:697–702. [PubMed]
8. Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB, Fitzsimmons WE, Uleman C. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl. 2004;10:1258–1262. [PubMed]
9. Rayhill SC, Barbeito R, Katz D, Voigt M, Labrecque D, Kirby P, Miller R, et al. A cyclosporine-based immunosuppressive regimen may be better than tacrolimus for long-term liver allograft survival in recipients transplanted for hepatitis C. Transplant Proc. 2006;38:3625–3628. [PubMed]
10. Flisiak R, Horban A, Gallay P, Bobardt M, Selvarajah S, Wiercinska-Drapalo A, Siwak E, et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology. 2008;47:817–826. [PubMed]
11. Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y, Chen CH, et al. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology. 2005;129:1031–1041. [PubMed]
12. Yang F, Robotham JM, Nelson HB, Irsigler A, Kenworthy R, Tang H. Cyclophilin a is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J Virol. 2008;82:5269–5278. [PMC free article] [PubMed]
13. Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, Shimotohno K. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell. 2005;19:111–122. [PubMed]
14. Robida JM, Nelson HB, Liu Z, Tang H. Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. J Virol. 2007;81:5829–5840. [PMC free article] [PubMed]
15. Fernandes F, Poole DS, Hoover S, Middleton R, Andrei AC, Gerstner J, Striker R. Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. Hepatology. 2007 [PubMed]
16. Ago H, Adachi T, Yoshida A, Yamamoto M, Habuka N, Yatsunami K, Miyano M. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure. 1999;7:1417–1426. [PubMed]
17. Bressanelli S, Tomei L, Roussel A, Incitti I, Vitale RL, Mathieu M, De Francesco R, et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci U S A. 1999;96:13034–13039. [PubMed]
18. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol. 1999;6:937–943. [PubMed]
19. Di Marco S, Volpari C, Tomei L, Altamura S, Harper S, Narjes F, Koch U, et al. Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. J Biol Chem. 2005;280:29765–29770. [PubMed]
20. Nelson HB, Tang H. Effect of cell growth on hepatitis C virus (HCV) replication and a mechanism of cell confluence-based inhibition of HCV RNA and protein expression. J Virol. 2006;80:1181–1190. [PMC free article] [PubMed]
21. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A. 2005;102:9294–9299. [PubMed]
22. Chinnaswamy S, Yarbrough I, Palaninathan S, Kumar CT, Vijayaraghavan V, Demeler B, Lemon SM, et al. A locking mechanism regulates RNA synthesis and host protein interaction by the hepatitis C virus polymerase. J Biol Chem. 2008;283:20535–20546. [PMC free article] [PubMed]
23. Zhong W, Uss AS, Ferrari E, Lau JY, Hong Z. De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase. J Virol. 2000;74:2017–2022. [PMC free article] [PubMed]
24. Ranjith-Kumar CT, Kim YC, Gutshall L, Silverman C, Khandekar S, Sarisky RT, Kao CC. Mechanism of de novo initiation by the hepatitis C virus RNA-dependent RNA polymerase: role of divalent metals. J Virol. 2002;76:12513–12525. [PMC free article] [PubMed]
25. Shim JH, Larson G, Wu JZ, Hong Z. Selection of 3′-template bases and initiating nucleotides by hepatitis C virus NS5B RNA-dependent RNA polymerase. J Virol. 2002;76:7030–7039. [PMC free article] [PubMed]
26. Kim MJ, Kao C. Factors regulating template switch in vitro by viral RNA-dependent RNA polymerases: implications for RNA-RNA recombination. Proc Natl Acad Sci U S A. 2001;98:4972–4977. [PubMed]
27. Niesen FH, Berglund H, Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc. 2007;2:2212–2221. [PubMed]
28. Kao CC, Yang X, Kline A, Wang QM, Barket D, Heinz BA. Template requirements for RNA synthesis by a recombinant hepatitis C virus RNA-dependent RNA polymerase. J Virol. 2000;74:11121–11128. [PMC free article] [PubMed]
29. Kim CH, Kao CC, Tinoco I., Jr. RNA motifs that determine specificity between a viral replicase and its promoter. Nat Struct Biol. 2000;7:415–423. [PubMed]
30. Kato T, Date T, Murayama A, Morikawa K, Akazawa D, Wakita T. Cell culture and infection system for hepatitis C virus. Nat Protoc. 2006;1:2334–2339. [PubMed]
31. Butcher SJ, Makeyev EV, Grimes JM, Stuart DI, Bamford DH. Crystallization and preliminary X-ray crystallographic studies on the bacteriophage phi6 RNA-dependent RNA polymerase. Acta Crystallogr D Biol Crystallogr. 2000;56:1473–1475. [PubMed]
32. Shirota Y, Luo H, Qin W, Kaneko S, Yamashita T, Kobayashi K, Murakami S. Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity. J Biol Chem. 2002;277:11149–11155. [PubMed]
33. Dimitrova M, Imbert I, Kieny MP, Schuster C. Protein-protein interactions between hepatitis C virus nonstructural proteins. J Virol. 2003;77:5401–5414. [PMC free article] [PubMed]
34. Wiedmann B, Puyang X, Poulin D, Mathy JE, Ma S, Anderson LJ, Fujimoto R, Compton TG, Lin K. Characterization of Mechanism of Resistance to Cyclophilin Inhibitors in HCV Replicon; 15th International Symposium on Hepatitis C Virus and Related Viruses; San Antonio. Oct. 5-9 2008.